Pseudostellaria heterophylla Extract Polysaccharide H-1-2 Suppresses Pancreatic Cancer by Inhibiting Hypoxia-Induced AG2

Hongwei Sun,1,6 Keqing Shi,1,6 Kai Qi,2,6 Hongyu Kong,1 Qiye He,3,4 and Mengtao Zhou1,5

We aimed to examine the therapeutic potential of polysaccharide H-1-2, a bioactive component of Pseudostellaria heterophylla, against pancreatic cancer, as well as to demonstrate the underlying molecular mechanisms. Invasion and migration of pancreatic cells treated with H-1-2 were evaluated. A xenograft tumor mouse model was established to assess the effect of H-1-2 on tumor growth. Expression levels of hypoxic inducible factor-1α (HIF1α) and anterior gradient 2 (AGR2) were measured in pancreatic cells after H-1-2 treatment. Luciferase reporter and chromatin immunoprecipitation assays were conducted to investigate HIF1α regulation on AGR2. AGR2 expression was re-introduced into pancreatic cells to assess the role of AGR2 as a downstream effector of hypoxia after H-1-2 treatment. H-1-2 inhibited invasion and migration of pancreatic cancer cells, repressed xenograft pancreatic tumor growth, and increased survival of mice. H-1-2 repressed AGR2 expression in pancreatic cancer cells through the hypoxia response element (HRE) in its promoter region. Ectopic AGR2 expression partially negated the H-1-2 inhibitory effect on invasion and migration of pancreatic cells and on xenograft pancreatic tumors growth, and it also compromised the H-1-2 promotinal effect on survival of mice. We conclude that H-1-2 suppresses pancreatic cancer by inhibiting hypoxia-induced AGR2 expression, supporting further investigation into its efficacy against pancreatic cancer in clinical settings.

INTRODUCTION

Treatments for human cancer have advanced with the aid of recent progresses in cancer biology. However, pancreatic cancer fell drastically behind other types of tumors with regard to patient prognosis and survival.1 The overall 5-year survival rate of patients with pancreatic cancer is merely around 7%.2 Only about 10% of patients with pancreatic cancer are diagnosed when the disease is localized; therefore, less than 10% of diagnosed patients could be cured with surgical interventions. Furthermore, even among patients with localized cancer, the 5-year survival rate is only one in five. While multiple prominent morbidities associated with tumor, e.g., biliary sepsis, obstruction of gastric outlet and bile duct, tumor cachexia, and venous thromboembolism, are thought to contribute to the poor outcome, epidemiological investigations suggest that pancreatic tumor cells often mobilize and develop micrometastases at relatively early stages, thereby acquiring resistance to currently available adjuvant radiotherapy and/or chemotherapy.3 Hence, it is thought that pancreatic cancer fosters aggressive phenotypes at relatively early stages, different from other gastrointestinal cancers.

One essential player involved in the aggressive phenotype of pancreatic cancer is the microenvironment of the tumor tissues, which is characterized by extreme hypoxia.3 Hypoxic inducible factor-1α (HIF-1) is an essential player in the cellular adaption to hypoxic conditions, and it is enriched in most pancreatic tumor tissues. Prior investigations demonstrated that HIF-1α overexpression correlated with poor prognosis, but the underlying mechanisms remain unknown.4

Pseudostellaria heterophylla (P. heterophylla), also known as Prince Ginseng, has a history of application in Chinese traditional medicine.3 Composition analysis of P. heterophylla identified abundant fatty acids, amino acids, heterophyllin, polysaccharides, and diverse trace elements, among which the polysaccharides are considered to be the main constituent responsible for the beneficial effects of P. heterophylla.5 As early as decades ago, fractions from P. heterophylla have been proposed to stimulate the release of mitogenic and tumor necrosis factors.7,8 In particular, polysaccharide extracts from P. heterophylla were reported to exert immunostimulating activities against tumors.9 Furthermore, fractions of P. heterophylla that are enriched in polysaccharides could protect cardiomyocytes against cobalt chloride (CoCl2)-induced hypoxic injury,10 although...
the exact bioactive component responsible for the protection still remains unknown.

H-1-2, a novel homogeneous polysaccharide, was recently isolated from the polysaccharide fractions of the *P. heterophylla* extracts, which was later shown to inhibit hypoxia in human pancreatic β cells. These studies have prompted us to hypothesize that polysaccharide H-1-2 might exert the same anti-hypoxic activity in pancreatic cancer cells and suppress tumor progression. In addition, we sought to elucidate the downstream molecular mechanism responsible for the inhibitory effect of H-1-2 on pancreatic cancer.

RESULTS

H-1-2 Inhibits Invasion and Migration of Pancreatic Cancer Cells In Vitro

To examine the effect of H-1-2 on invasion and migration of pancreatic cancer cells in vitro, we performed Transwell invasion and wound healing assays in both PANC-1 and PaCa-2 cells after treatments with vehicle or H-1-2, respectively. Invasiveness of both cell lines were significantly reduced by H-1-2 compared to the vehicle control (Figures 1A and 1B). Similarly, the same reduction trend was observed in the migration of both cell lines (Figures 1C and 1D). These findings indicated that in vitro growth of pancreatic cancer cells PANC-1 and PaCa-2 was suppressed by H-1-2.

H-1-2 Inhibits Growth of Xenograft Pancreatic Tumors and Increases Survival of Mice Bearing Xenograft Tumors

Next, we sought to experimentally validate the above observation in vivo with a xenograft pancreatic tumor mouse model. Our results unambiguously demonstrated that administration of H-1-2 significantly suppressed xenograft tumor growth (Figure 2A), which firmly consolidated the anti-tumor property of H-1-2 in vivo. Consistently, the weight of xenograft tumor resected at the endpoint of the experiment manifested the remarkable reduction in the H-1-2-treated mice (Figure 2B). Our data for the first time uncovered the suppressive effect of H-1-2 on pancreatic cancer progression in vivo. Furthermore, Kaplan-Meier analysis unraveled the prominent therapeutic effect of H-1-2, which significantly prolonged the overall survival time of mice bearing xenograft tumors in comparison with the vehicle group (Figure 2C).

HIF1α and Anterior Gradient 2 (AGR2) mRNA Are Upregulated in Pancreatic Cancer Patient Tumor Tissues

We further investigated the potential downstream effectors responsible for the anti-tumor actions of H-1-2. HIF1α is a major regulator of cellular adaption to hypoxia and is enriched in most pancreatic cancer tissues. As expected, by comparing its expression level between pancreatic cancer patient tumor and adjacent normal tissues, we found HIF1α to be significantly upregulated in the patient tumors (Figure 3A). AGR2 was reported to be upregulated by HIF1α. We therefore reasoned that elevated HIF1α in pancreatic tumor tissues could lead to upregulated AGR2 expression as well, which was indeed confirmed by higher AGR2 mRNA levels in pancreatic tumor tissues than adjacent normal tissues (Figure 3B).

H-1-2 Inhibits AGR2 and HIF1α in Pancreatic Cancer

Next, we sought to elucidate the molecular mechanism underlying the anti-tumor property of H-1-2 in pancreatic cancer. In view of the possible oncogenic contribution of AGR2 as indicated by our previous data, here we attempted to determine the relative expression of AGR2 in response to H-1-2 treatment. To this end, AGR2 mRNA was extracted from both pancreatic cancer cell lines and xenograft tumors after mice were sacrificed. Our quantitative real-time PCR results demonstrated that H-1-2 significantly repressed expression of AGR2 at the transcriptional level in both cell culture and xenograft tumors (Figures 4A and 4C). Consequently, AGR2 protein levels were also greatly reduced in the H-1-2-treated cell culture and in
mice in comparison with vehicle control (Figures 4B and 4D). Notably, H-1-2 treatment also suppressed HIF1α protein levels (Figures 4B and 4D), confirming the previously reported anti-hypoxic property of H-1-2.10,12

**H-1-2 Downregulates AGR2 Expression through the Hypoxia-Responsive Element (HRE) in Its Promoter Region**

HIF1α was reported to promote AGR2 expression via the HRE from −937 to −912 bp on the AGR2 promoter sequence.13 To experimentally interrogate the modulation of AGR2 expression by HIF1α, we constructed wild-type or mutated HRE-fused luciferase reporter plasmids (Figure 5A). Under hypoxic conditions (100 μM CoCl2), luciferase activity of the wild-type construct was severely compromised compared to under normoxic conditions, whereas the mutated HRE construct was unaffected (Figure 5B). As expected, as H-1-2 was able to induce hypoxia, H-1-2 treatment elicited a significant inhibition on the luciferase activity of the wild-type, but not the mutated, construct, using the hypoxia condition as a positive control (Figure 5C). In addition, the direct binding of HIF1α onto the HRE of AGR2 was assessed using a chromatin immunoprecipitation (ChIP) assay, which revealed a marked enrichment of the AGR2 HRE segment in the HIF1α-immunoprecipitated complex under hypoxic conditions (Figure 5D). Similarly, H-1-2 treatment was also able to induce strong binding of HIF1α antibody to the AGR2 HRE (Figure 5E), showing a similar effect as the hypoxia positive control (Figure 5D). These findings clearly indicated that HIF1α directly bound to the HRE on AGR2 promoter to enhance its expression. It is also obvious that the anti-hypoxic property of H-1-2 was indeed responsible for its inhibitory effect on AGR2 expression, because both AGR2 mRNA and proteins were significantly upregulated by the hypoxic condition (100 μM CoCl2) in pancreatic cells (Figures 5F and 5G).

**Ectopic AGR2 Expression Partially Negates the H-1-2 Beneficial Effect against Pancreatic Cancer**

Our previous data demonstrated the anti-tumor property of H-1-2, which specifically inhibited AGR2 expression. Next, we sought to elucidate whether the repressed HIF1α expression played an essential role to mediate the anti-tumor effects of H-1-2. We introduced ectopic expression of AGR2 into H-1-2-treated pancreatic cells to antagonize the H-1-2-induced AGR2 inhibition, and this fully rescued AGR2 expression to comparable levels as for untreated cells (Figures 6A and 6B). We then examined the invasion and migration of these cells and discovered that the re-expression of AGR2 attenuated the inhibitory effects of H-1-2 on the in vitro growth of pancreatic cell lines, but only to a certain extent and not fully restored to levels seen in untreated cells (Figures 6C and 6D).

Similarly, a partially compromised H-1-2 anti-tumor effect by AGR2 re-expression was also observed in vivo: ectopic introduction of AGR2 could restore the xenograft tumor growth (Figure 7A), and the weight of xenograft tumor at the endpoint was increased by re-expression of AGR2 in H-1-2-treated mice (Figure 7B), but not to control levels in both cases. Moreover, we observed significantly shortened survival of mice after injection with cells with re-introduced AGR2 even though mice were administered H-1-2, but the lifespans of these mice were nevertheless longer than those of control mice without H-1-2 treatment (Figure 7C). Finally, the extracted xenograft tumors at the endpoint were subjected to western blot analysis, which indicated complete rescue of AGR2 protein levels upon its ectopic expression in the H-1-2-treated group (Figure 7D).

**DISCUSSION**

In this study, we showed that treatment of the single-component polysaccharide H-1-2 was able to inhibit invasion and migration of pancreatic cancer cells in vitro, and xenograft pancreatic tumor growth in vivo, as well as to improve survival of mice bearing the xenograft pancreatic tumors. In searching for the underlying molecular effectors of H-1-2, we discovered that HIF1α and AGR2 mRNA were upregulated in tumor tissues of pancreatic cancer patients, both of which were previously implicated in the tumorigenesis of pancreatic cancer.14 Indeed, our results indicated that H-1-2 could inhibit AGR2 and HIF1α expression in pancreatic cancer both in vitro and in vivo. Through a luciferase reporter assay and ChIP, we have established a direct interaction between HIF1α protein and HRE on the promoter of AGR2 gene, which is responsible for the observed hypoxic induction of AGR2 expression. We therefore speculated that H-1-2 likely downregulated AGR2 expression through its anti-hypoxic property. To test this hypothesis, ectopic AGR2 expression was re-introduced into H-1-2-treated pancreatic cells, and this partially negated the H-1-2 inhibitory effect on cell invasion and migration abilities. Moreover, in the mouse model, ectopic AGR2 expression also negated the H-1-2 inhibitory effect on growth of xenograft pancreatic tumors and the H-1-2 promotional effect on survival of mice. These data clearly support the conclusion that H-1-2 suppresses pancreatic cancer by inhibiting hypoxia-induced AGR2 (Figure 8).
Anterior gradient (AG) genes were initially identified in *Xenopus laevis*, and AGR2 is one of the human homologs. Human AGR2 belongs to the protein disulfide isomerase (PDI) family of endoplasmic reticulum (ER)-resident proteins, with strong expression in the stomach, lung, prostate, small intestines, and colon. A structural relationship between the functional domains of AGR2 and the PDI family of molecular chaperones indicates potential AGR2 activity in protein folding. An increase in AGR2 levels has been reported in a variety of tumor tissues, but the molecular events resulting in the elevated AGR2 in tumor cells, as well as the clinical outcomes of AGR2 upregulation in tumors, remain largely unknown. Particularly in the context of pancreatic cancer, AGR2 was reported to be expressed and secreted during the progression of pancreatic cancer to promote the survival of cancer cells. Furthermore, as an ER stress protein, AGR2 reportedly preceded and contributed to the initiation of pancreatic cancer. In pancreatic intraepithelial neoplasia, AGR2 acts as a SMAD4-suppressible gene that regulates MUC1 levels and stimulates the initiation and progression of cancer. Importantly, an elevated level of AGR2 in pancreatic cancer tissues was verified using immunohistochemistry, cDNA, and tissue microarrays, while downregulation of AGR2 led to cell apoptosis and attenuated chemotherapy resistance of pancreatic cancer cells through the extracellular signal-regulated kinase (ERK)/AKT axis. These findings suggest that AGR2 promotes the survival of pancreatic cancer cells and endows tumor cells with the protection from chemotherapeutic treatments, which possibly contributes to the fact that pancreatic cancer is widely recognized as highly resistant to therapeutic interventions. Our results, where H-1-2 repressed AGR2 expression in pancreatic cancer cells through its anti-hypoxic function, provide yet another instance implicating AGR2 as an important prognosis factor for treatment against pancreatic cancer.

Clinical studies have clearly demonstrated that hypoxia is a common feature shared by various solid tumors. Normal tissues are generally under an oxygen (O2) pressure of 30–50 mm Hg, which decreases to below 2.5 mm Hg in up to half of locally advanced solid tumors. Measurement of O2 levels using pO2 histography in patients with several solid tumors revealed that pancreatic cancer was associated with the most hypoxic conditions. Similarly, intraoperative pO2 measurements of seven resectable pancreatic cancer tissues further confirmed the hypoxic microenvironment. Under normoxic conditions, HIF1α is constitutively hydroxylated.
by prolyl hydroxylase and subsequently ubiquitinated by the von Hippel-Lindau (VHL) gene, which results in the degradation via the ubiquitin-proteasome system. In response to the reduced oxygen supply, HIF1α is stabilized, accumulated, and forms heterodimers with HIF1β to transcriptionally activate various downstream genes. In the context of this study, H-1-2 exerts its beneficial role against pancreatic cancer by targeting hypoxia/HIF1α, supporting HIF1α as a promising therapeutic target in pancreatic cancer treatments.

Hypoxic regulation of AGR2 in tumor biology has been previously documented. For instance, in glioblastoma, AGR2 was increased by HIF1α, which led to enhanced migration and tube formation capabilities of cells in vitro and increased growth and vascularity of tumor xenografts in vivo. Alternatively, AGR2 was regarded as a binding stabilizer of HIF1α, thereby contributing to the hypoxia-induced doxorubicin resistance in breast cancer. However, no prior investigation has been conducted on the role of hypoxia/AGR2 regulation in pancreatic cancer. In line with this, our current study is the first instance to provide evidence demonstrating the direct involvement of hypoxia-regulated AGR2 in tumorigenesis of human pancreatic cancer. Using a luciferase reporter assay, we have shown that the -937- to -912-bp promoter region upstream of the AGR2 open reading frame is an HRE. In addition, this HRE was able to directly recruit HIF1α binding in a ChIP assay.

Notably, although ectopic expression of AGR2 almost fully rescued its expression in H-1-2-treated pancreatic cancer cells to comparable level as untreated cells, it did not completely abolish the beneficial
effect of H-1-2 on pancreatic cancer cells. Instead, it only partially restored the invasion and migration abilities in vitro and xenograft tumor growth in vivo. This observation raises the possibility that, besides AGR2, there are likely other downstream targets of HIF1α participating in the tumorigenesis of pancreatic cancer, which calls for further investigations.

Conclusion
To conclude, we have demonstrated a beneficial therapeutic effect of polysaccharide H-1-2, a bioactive component of P. heterophylla, against pancreatic cancer both in vitro and in vivo. H-1-2 inhibits hypoxia, which consequently downregulates AGR2 expression, to suppress pancreatic tumor. Our current study supports further investigation into the efficacy of H-1-2 against pancreatic cancer in clinical settings. This study is, however, limited in the following aspects: (1) the relatively small number of clinical samples, and (2) the observed mechanism needs to be verified in clinic.

MATERIALS AND METHODS

Cell Lines
Two pancreatic cell lines, PaCa-2 and PANC-1, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA) and 10% fetal bovine serum (FBS; Invitrogen, Waltham, MA, USA) in a humidified incubator supplied with 5% CO2 at 37°C. Both cell lines were verified using the short tandem repeat analysis. H-1-2 was purified with purity >95% and prepared in culture media to a final concentration of 100 μg/mL according to a previous report.

Transwell Invasion Assay
Transwell invasion assay was performed using inserts of 8-μm pore size (BD Biosciences, Franklin Lakes, NJ, USA) inside a 24-well plate. Cells at a density of 1 × 10^5 cells per well were seeded into the upper compartment containing the Matrigel-coated membrane, then 500 μL of medium supplemented with 10% FBS was added to the lower compartment to engage cells. Next, cultures were maintained in a 5% CO2 humidified incubator at 37°C for 24 h, followed by treatment with 20 μM 5-ethynyl-2’-deoxyuridine at 37°C for another 4 h. After that, inserts were detached to be visualized using the ENU kit (Invitrogen, Waltham, MA, USA). To calculate the invasion rate, cells were quantified from six randomly selected fields for each individual well and normalized to the appropriate control.

Scratch Migration Assay
Cells were cultured in six-well plates and allowed to reach 100% confluence, and then starved in growth media without FBS in the presence of 10 μg/mL mitomycin C (Sigma-Aldrich, St. Louis, MO, USA). For the wound-healing assay, a linear incision was made across the cell monolayer with the tip of a 100-μL sterile pipette, and cultures were subsequently washed with phosphate-buffered saline (PBS) to remove the debris. Cells were cultured in the presence of 10 μg/mL mitomycin C for another 24 h. The distance that the wound edge moved was measured to calculate the migration rate, which was normalized to the appropriate control.

Xenograft Mouse Model
The NSG immunodeficient mice were obtained from Biocytogen (Beijing, China) and allowed to acclimate for at least 1 week before experiments. Mice were housed in the specific pathogen-free (SPF) environment with free access to feed and sterile drinking water. All animal experiments were executed in conformity with the Guide for the Care and Use of Laboratory Animals by the NIH. The protocols and experimental design were approved by the Animal Ethics Committee of The First Affiliated Hospital of Wenzhou Medical
University. To establish the xenograft mouse model, 10^6 cells in 100 μL of vehicle were subcutaneously inoculated into the lower flank of the animal. The growth of the tumor was regularly monitored and recorded. H-1-2 (1.5 g/kg body weight) was delivered via oral gavage for 30 consecutive days and controlled by drinking water as previously established. No side effects were observed in animals administered with the indicated dose of H-1-2.

Patient Samples

The clinical samples were collected from 10 pancreatic cancer patients in The First Affiliated Hospital of Wenzhou Medical University. To pathologically confirm by three experts independently. Pancreatic cancer tissues, together with paired adjacent normal tissues, were harvested during surgical procedures and immediately snap-frozen with liquid nitrogen for further analysis. The protocols were approved and authorized by the Ethics Committee of The First Affiliated Hospital of Wenzhou Medical University. All enrolled patients provided written informed consents.

Quantitative Real-Time PCR

Total RNA of the exponential cells was extracted with a TRIzol reagent kit (Invitrogen, Waltham, MA, USA). The concentration of RNA was assessed using the NanoDrop 1000 (Thermo Fisher Scientific, Waltham, MA, USA), and the integrity of RNA samples was examined through agarose electrophoresis. Preparation of cDNA was immediately performed using a high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific, Waltham, MA, USA) with mixed oligo(dT) and random primers. Quantitative real-time PCR was conducted using SYBR Green real-time PCR master mixes (Thermo Fisher Scientific, Waltham, MA, USA), and the relative expression of genes was calculated using the 2^(-ΔΔCt) method. Primers used in the current study were as follows: HIF1α forward 5’-AGGTGGATATGTCTGGGT-3’, reverse 5’-AAGGACACATTCTGTTTGTTG-3’; AGR2 forward 5’-GGAGGACAACTGCTCTGCCAA-3’, reverse 5’-TCCAAGACAAACAAACCTTG-3’; GAPDH forward 5’-CTGACTTCAACAGCGACACC-3’, reverse 5’-TAGCCAACATTGTGTCATAC-3’.

Western Blot

Cell lysate was prepared in standard radioimmunoprecipitation assay (RIPA) lysis buffer and the protein content was quantified using the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Waltham, MA, USA). Samples of equal amounts of protein were resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently transferred onto polyvinylidene fluoride membrane on ice. The membrane was then blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween 20 (TBST) buffer on a shaker at
room temperature for 1 h and subjected to incubation with the primary antibodies (anti-HIF1α, Cell Signaling Technology, 1:1,000; anti-AGR2, Novus Biologicals, 1:250; anti-GAPDH, Abcam, 1:1,000) overnight at 4°C. After six washes with TBST (5 min each), the membrane was blotted with the appropriate secondary antibody at room temperature for 1 h and then visualized using a commercial enhanced chemiluminescence (ECL) kit (Millipore, Billerica, MA, USA). GAPDH was used as the internal loading control.

Luciferase Reporter Assay

The promoter region of AGR2 including the putative HRE was subcloned into the pGL3 luciferase reporter plasmid for transient transfection using Lipofectamine 2000. The recipient cells were exposed to either normoxic (0 μM CoCl2) or hypoxic (100 μM CoCl2) conditions. The relative luciferase activities were examined 24 h after transfection using the commercially available Bright-Glo luciferase reporter system (Promega, Madison, WI, USA).

ChIP

The ChIP assay was conducted using commercially available kits obtained from Abcam (Ab500, Cambridge, MA, USA) following the manufacturer’s instructions. In brief, the exponential cells exposed to hypoxia-mimicking stimulations were first crosslinked with 1% formaldehyde at room temperature for 20 min and then transferred to lysis buffer on ice for 10 min. The cell lysate was centrifuged, the supernatant was discarded, and the chromatin pellet was re-suspended and subjected to ultrasonic shearing with three 15-s pulses to lysis buffer on ice for 10 min. The cell lysate was centrifuged, the supernatant was discarded, and the chromatin pellet was re-suspended and subjected to ultrasonic shearing with three 15-s pulses with one 30-s interval of rest on ice in between. The target chromatin fragments were immunoprecipitated using HIF1α antibody overnight at 4°C and released through incubation with RNase and proteinase K in DNA release buffer for 30 min at 42°C. The enrichment of candidate promoters was evaluated by subsequent PCR.

Ectopic AGR2 Expression

The full-length cDNA sequence of the human AGR2 open reading frame was PCR amplified and cloned into the pcDNA3.1 vector (Life Technologies, Pleasanton, CA, USA), using standard molecular cloning protocol.

Statistical Analysis

The results were obtained from three independent biological repeats unless otherwise specified and presented as mean ± standard deviation (SD). Data were analyzed using GraphPad Prism 7.0 software. The one-way ANOVA followed by a Tukey test was performed for statistical comparison. p < 0.05 was considered statistically significant.

AUTHOR CONTRIBUTIONS

H.S., K.S., Q.H., and Q.H. conducted the experiments; M.Z. designed the study; and H.S., K.S., Q.H., and M.Z. wrote the manuscript.

CONFLICTS OF INTEREST

The authors declare no competing interests.

ACKNOWLEDGMENTS

This work was funded by an internal funding source in our hospital.

REFERENCES

1. Erickson, L.A., Highsmith, W.E., Jr., Fei, P., and Zhang, J. (2015). Targeting the hypoxia pathway to treat pancreatic cancer. Drug Des. Devel. Ther. 9, 2029–2031.

2. Miller, K.D., Siegel, R.L., Lin, C.C., Mariotito, A.B., Kramer, J.L., Rowland, J.H., Stein, K.D., Alteri, R., and Jemal, A. (2016). Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66, 271–289.

3. Erkan, M., Kurtoglu, M., and Kleeff, J. (2016). The role of hypoxia in pancreatic cancer: a potential therapeutic target? Expert Rev. Gastroenterol. Hepatol. 10, 301–316.

4. Shiroy, T., Nagao, M., Ikeba, N., Kanehiro, H., Hisanaga, M., Ko, S., Fukumoto, A., and Nakajima, Y. (2003). Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res. 23 (6C), 4711–4717.

5. Yang, J., Wang, D.Q., Yao, Y., and Jin, X.F. (2011). [Observation on biological characteristics of wild Pseudostellaria heterophylla]. Zhong Yao Cai 34, 1323–1326.

6. Wang, J., Li, J., Li, H., Wu, X., and Gao, W. (2015). HPLC-ESI-MSn analysis, fed-batch cultivation enhances bioactive compound biosynthesis and immune-regulative effect of adventitious roots in Pseudostellaria heterophylla. Appl. Biochem. Biotechnol. 177, 63–75.

7. Wong, C.K., Leung, K.N., Fung, K.P., Pang, P.K., and Choy, Y.M. (1992). Mitogenic and tumor necrosis factor producing activities of Pseudostellaria heterophylla. Int. J. Immunopharmacol. 14, 1315–1320.

8. Wong, C.K., Leung, K.N., Fung, K.P., Pang, P.K., and Choy, Y.M. (1994). Tumor necrosis factor eliciting fractions separated from Pseudostellaria heterophylla. Int. J. Immunopharmacol. 16, 271–277.

9. Wong, C.K., Leung, K.N., Fung, K.P., and Choy, Y.M. (1994). The immunostimulating activities of anti-tumor polysaccharides from Pseudostellaria heterophylla. Immunopharmacology 28, 47–54.

10. Wang, Z., Lao, S.G., He, Y., Li, J., Zhang, R.F., He, X., Liu, Y., Xiao, T.T., Lan, Y.Y., Long, Q.D., and Wang, Y.L. (2013). Protective effects of fractions from Pseudostellaria heterophylla against cobalt chloride-induced hypoxic injury in Hep2c cell. J. Ethnopharmacol. 147, 540–545.

11. Chen, J., Pang, W., Shi, W., Yang, B., Kan, Y., He, Z., and Hu, J. (2016). Structural elucidation of a novel polysaccharide from Pseudostellaria heterophylla and stimulating glucose uptake in cells and distributing in rats by oral. Molecules 21, 21.

12. Fang, Z.H., Duan, X.C., Zhao, J.D., Wu, Y.J., and Liu, M.M. (2018). Novel polysaccharide H-1.2 from Pseudostellaria heterophylla alleviates type 2 diabetes mellitus. Cell. Physiol. Biochem. 49, 996–1006.

13. Li, Z., Zhu, Q., Hu, L., Chen, H., Wu, Z., and Li, D. (2015). Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2 -induced doxorubicin resistance in breast cancer cells. Cancer Sci. 106, 1041–1049.

14. Ramachandran, V., Arumugam, T., Wang, H., and Logsdon, C.D. (2008). Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res. 68, 7811–7818.

15. Sive, H.L., Hattori, K., and Weintraub, H. (1989). Progressive determination during formation of the anteroposterior axis in Xenopus laevis. Cell 58, 171–180.

16. Persson, S., Rosenquist, M., Knooblach, B., Khorov-Far, R., Sommarin, M., and Michalak, M. (2005). Diversity of the protein disulde isomerase family: identification of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol. Phylegenet. Evol. 36, 734–740.

17. Thompson, D.A., and Weigel, R.J. (1998). hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem. Biophys. Res. Commun. 251, 111–116.

18. Park, S.-W., Zhen, G., Verhaeghe, C., Nakagami, Y., Nguyen, L.T., Barczak, A.J., Killeen, N., and Erle, D.J. (2009). The protein disulde isomerase AGR2 is essential for production of intestinal mucus. Proc. Natl. Acad. Sci. USA 106, 6950–6955.

19. Brychtova, V., Vojtesek, B., and Hrstka, R. (2011). Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett. 304, 1–7.

20. Dumartin, L., Alrawashdeh, W., Trabulo, S.M., Radon, T.P., Steiger, K., Feakins, R.M., di Magliano, M.P., Heeschen, C., Esposito, I., Lemoine, N.R., and Cmogorac-Jurcevic, M. (2016). Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66, 271–289.
T. (2017). ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Oncogene 36, 3094–3103.

21. Norris, A.M., Gore, A., Balboni, A., Young, A., Longnecker, D.S., and Korc, M. (2013). AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene 32, 3867–3876.

22. Iacobuzio-Donahue, C.A., Ashfaq, R., Maitra, A., Adsay, N.V., Shen-Ong, G.L., Berg, K., Hollingsworth, M.A., Cameron, J.L., Yeo, C.J., Kern, S.E., et al. (2003). Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63, 8614–8622.

23. Missiaglia, E., Blaveri, E., Terris, B., Wang, Y.-H., Costello, E., Neoptolemos, J.P., Crnogorac-Jurcevic, T., and Lemoine, N.R. (2004). Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int. J. Cancer 112, 100–112.

24. Liu, Q.G., Li, Y.J., and Yao, L. (2018). Knockdown of AGR2 induces cell apoptosis and reduces chemotherpay resistance of pancreatic cancer cells with the involvement of ERK/AKT axis. Pancreatology 18, 678–688.

25. Vaupel, P., and Mayer, A. (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225–239.

26. Vaupel, P., Höckel, M., and Mayer, A. (2007). Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signal. 9, 1221–1235.

27. Koong, A.C., Mehta, V.K., Le, Q.T., Fisher, G.A., Terris, D.J., Brown, J.M., Bastidas, A.J., and Vierra, M. (2000). Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 48, 919–922.

28. Minervini, G., Quaglia, F., and Tosatto, S.C. (2015). Insights into the proline hydroxylase (PHD) family, molecular evolution and its impact on human health. Biochemie 116, 114–124.

29. Lee, J.H., Elly, C., Park, Y., and Liu, Y.C. (2015). E3 ubiquitin ligase VHL regulates hypoxia-inducible factor-1α to maintain regulatory T cell stability and suppressive capacity. Immunity 42, 1062–1074.

30. Jiang, B.H., Rue, E., Wang, G.L., Roe, R., and Semenza, G.L. (1996). Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271, 17771–17778.

31. Hong, X.Y., Wang, J., and Li, Z. (2013). AGR2 expression is regulated by HIF-1 and contributes to growth and angiogenesis of glioblastoma. Cell Biochem. Biophys. 67, 1487–1495.

32. Hu, J., Pang, W., Chen, J., Bai, S., Zheng, Z., and Wu, X. (2013). Hypoglycemic effect of polysaccharides with different molecular weight of Pseudostellaria heterophylla. BMC Complement. Altern. Med. 13, 267.